Siga Technologies INC Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Siga Technologies INC (SIGA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 0 shares for the 12-month period ending 2015-12-31, per its 10-K filed 2016-03-04.
Discontinued › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2016-03-04
- Siga Technologies INC share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2015 was 0.00 shares.
- Siga Technologies INC share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2014 was 0.00 shares, a 100.00% decline from fiscal 2013.
- Siga Technologies INC share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2013 was 27.00K shares, a 82.84% decline from fiscal 2012.
- Siga Technologies INC share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2012 was 157.35K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|
| 2015-12-31 | 0.00 shares 10-K · filed 2016-03-04 |
| 2014-12-31 | 0.00 shares 10-K · filed 2015-03-06 |
| 2013-12-31 | 27.00K shares 10-K · filed 2014-03-10 |
| 2012-12-31 | 157.35K shares 10-K/A · filed 2013-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |